Irlab Therapeutics Executive Interview Edison Group In this video, dr gunnar olsson, irlab therapeutics’ ceo, and dr nicholas waters, head of r&d, provide a detailed overview of the clinical development of mesdopetam and pirepemat. Edison’s soo romanoff recently caught up with kristina torfgård, new ceo of irlab therapeutics ab to discuss the drug development. watch the full interview here: lnkd.in g6rmjszu.
Irlab Therapeutics Executive Interview Edison Group Irlab therapeutics (irlab a) is a sweden based biotechnology company focused on developing novel drugs for the treatment of neurodegenerative diseases, with. Edison advisors leverages our core research platform to provide differentiated services including investor relations, esg and strategic consulting. all interviews have been prepared and issued by edison for publication globally. In this video we speak to kristina torfgård, irlab’s new ceo as of august 2024, and learn more about her wealth of experience in drug development, what drew her to irlab and her strategic priorities as the company approaches key upcoming milestones. In this interview, edison’s soo romanoff talks to irlab’s ceo gunnar olsson about the company’s action plan and strategic priorities as it approaches these inflection points.
Irlab Therapeutics Executive Interview Edison Group In this video we speak to kristina torfgård, irlab’s new ceo as of august 2024, and learn more about her wealth of experience in drug development, what drew her to irlab and her strategic priorities as the company approaches key upcoming milestones. In this interview, edison’s soo romanoff talks to irlab’s ceo gunnar olsson about the company’s action plan and strategic priorities as it approaches these inflection points. Despite substantial efforts to develop disease modifying approaches in pd, symptomatic treatment remains the mainstay. in this interview, ceo gunnar olsson provides a recap of irlab’s ongoing central nervous system efforts and pipeline. Based in sweden, irlab therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its isp technology platform. its two lead assets, mesdopetam and pirepemat, are in late stage clinical trials for the symptomatic treatment of parkinson’s disease (pd). In this interview, irlab’s executive vice president and head of r&d (previously ceo) nicholas waters provides an update on the company’s strategy and pipeline. Irlab therapeutics (omx: irlab a) is a sweden based biopharma company focused on the development of novel treatments for neurodegenerative diseases, with a particular focus on parkinson’s disease (pd).
Irlab Therapeutics Executive Interview Edison Group Despite substantial efforts to develop disease modifying approaches in pd, symptomatic treatment remains the mainstay. in this interview, ceo gunnar olsson provides a recap of irlab’s ongoing central nervous system efforts and pipeline. Based in sweden, irlab therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its isp technology platform. its two lead assets, mesdopetam and pirepemat, are in late stage clinical trials for the symptomatic treatment of parkinson’s disease (pd). In this interview, irlab’s executive vice president and head of r&d (previously ceo) nicholas waters provides an update on the company’s strategy and pipeline. Irlab therapeutics (omx: irlab a) is a sweden based biopharma company focused on the development of novel treatments for neurodegenerative diseases, with a particular focus on parkinson’s disease (pd).
Irlab Therapeutics Edison Group In this interview, irlab’s executive vice president and head of r&d (previously ceo) nicholas waters provides an update on the company’s strategy and pipeline. Irlab therapeutics (omx: irlab a) is a sweden based biopharma company focused on the development of novel treatments for neurodegenerative diseases, with a particular focus on parkinson’s disease (pd).
Irlab Therapeutics Edison Group
Comments are closed.